Observational studyClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026
Treatment Adherence With an Oral 9-Month Regimen for Rifampicin-Resistant Tuberculosis in South Africa.
Observational study in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAdherence to anti-tuberculosis (TB) therapy is an important determinant of treatment outcome in rifampicin-resistant tuberculosis (RR-TB). Understanding adherence to contemporary treatment regimens in routine care is needed to support implementation in TB programs. We aimed to characterize temporal adherence patterns among people receiving oral treatment for RR-TB.
methodsWe conducted a prospective observational cohort study at a referral TB hospital in South Africa. People aged ≥15 years with pulmonary RR-TB starting an oral 9- to 12-month regimen were included. Treatment adherence was measured using a digital pillbox during ambulatory care and with directly observed therapy during hospital care. The primary outcome was proportion of adherence days through 9 months. Latent class group-based trajectory modeling was used to identify temporal adherence patterns.
resultsOf 248 participants, 209 (84.3%) had assessable adherence data from the digital pillbox or directly observed therapy. Overall median adherence was 82% (interquartile range [IQR], 63%-98%) with combined measures, and 72% (IQR, 51%-92%) with digital pillbox only. Four distinct adherence patterns were identified. Adherence was 93%-100% in the first month. Two groups, representing 136 (65.1%) individuals, had small reductions in adherence over time, separated by higher and lower early adherence. In the other 2 groups, there was a 50% reduction in adherence by month 3 (48/209 [23.0%]) and month 6 (25/209 [12.0%]), respectively. Lower adherence over time was associated with having exclusive ambulatory care, treatment with the shorter regimen only, and age <40 years.
conclusionsTreatment adherence declined over time in distinct temporal patterns. Group characteristics could identify individuals who may benefit from enhanced treatment support.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.